Search PubMed⌕ Search

Biomedical subjects

J T Scott

Publications and source records attributed to J T Scott.

At least 37 records · Page 2Linked to original sources
PubMed1990

Antinuclear antibodies and the diagnosis of systemic lupus erythematosus in patients with acute intermittent porphyria.

To investigate the previously postulated association of systemic lupus erythematosus (SLE) and porphyria 38 patients with various types of porphyria were investigated for clinical and laboratory evidence of a connective tissue disease. Antinuclear antibodies (ANAs) were found in 8/15 (53%) patients with acute intermittent porphyria. These patients were more likely to have had a recent acute attack of porphyria, but only one patient had clinical evidence of SLE. Antinuclear antibodies were not found in any patients with latent acute intermittent porphyria or appreciably in any of the other types of porphyria studied. This finding of ANAs in patients with acute intermittent porphyria may explain the previously described association with SLE. Strict diagnostic criteria need to be used in any one patient as these two disorders have many similar clinical manifestations.

Adult↗
PubMed1989

Alcohol and gout.

Explore the source record for details and available documents.

Alcohol Drinking↗
PubMed1989

Systemic lupus erythematosus and acute intermittent porphyria.

A patient with systemic lupus erythematosus who subsequently developed attacks of acute intermittent porphyria is described. This case illustrates both the problems involved in the diagnosis and management of two disorders which share several clinical manifestations, and the influence of a connective tissue disease and its treatment on the expression of acute porphyria. The inter-relationship between these disorders and their possible association is discussed.

Acute Disease↗
PubMed1989

Chronic synovitis of the shoulder in familial Mediterranean fever: a disease of symptoms not signs.

Severe shoulder pain in a 41 year old Arab woman persisted for three months despite non-steroidal anti-inflammatory drug treatment. Isotope bone scanning and computed tomography showed inflammation of the glenohumeral joint and a large effusion, which needle aspiration had initially failed to reveal. A diagnosis of familial Mediterranean fever was made on the basis of a strongly suggestive past personal and family history, sterility of the joint effusion, and a good response to colchicine.

Adult↗
PubMed1989

Intermittent control of hyperuricemia in the treatment of gout.

Fifty patients with gout were randomly allocated to one of 2 groups receiving allopurinol, either continuously or for 2 months every year. Patients with renal functional impairment or tophacous gout were excluded. Duration of treatment ranged from 2-4 years. Acute gouty arthritis occurred to a similar degree in the 2 groups during the first year, but thereafter attacks occurred with diminishing frequency in the continuous group compared with the intermittent group. We concluded that the intermittent administration of allopurinol as given here is less effective in controlling symptoms of gout than continuous therapy.

Allopurinol↗
PubMed1987

Gout.

Explore the source record for details and available documents.

Arthritis↗
PubMed1985

Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.

Flurbiprofen has been compared with phenylbutazone in a double-blind study involving 33 patients with acute gout. Patients received either flurbiprofen 400 mg daily for 48 h followed by 200 mg daily, or phenylbutazone 800 mg daily for 48 h followed by 400 mg daily. The drugs were of comparable efficacy, while side-effects were uncommon and relatively mild. Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis.

Adult↗
PubMed1984

The uricosuric action of azapropazone: dose-response and comparison with probenecid.

Azapropazone is an anti-inflammatory agent with reported uricosuric properties. The aim of the present study was to extend these observations, by examining the dose-response and to compare the uricosuric effect of azapropazone with that of probenecid. Patients were given varying doses of azapropazone from 900-2400 mg daily for 4-day periods at separated intervals. Plasma uric acid levels were measured before and at the end of each treatment period. Three other patients maintained on low purine diets were given a 4-day course of 1200 mg azapropazone daily followed at an interval by a 4-day period of probenecid 1 g daily. Plasma uric acid levels and 24 h urinary uric acid excretion were compared. The mean fall in plasma uric acid level after four days of 900 mg azapropazone daily was 31.4% (n = 9) compared with 33.9% (n = 12) on 1200 mg daily; 42.3% (n = 10) on 1800 mg daily; and 46% (n = 6) on 2400 mg daily, indicating a graded dosage response. In the three patients on low purine diets the falls in plasma uric acid levels on probenecid 1 g daily were 50.5%, 46% and 29% compared with 33.5%, 32% and 20% respectively on azapropazone 1200 mg daily. Similarly the total amount of uric acid excreted in the urine by each patient during the 4-day period on probenecid 1 g daily was 14.01; 13.03 and 8.97 mmol compared with 23.53, 10.9 and 7.69 mmol on azapropazone 1200 mg daily.(ABSTRACT TRUNCATED AT 250 WORDS)

Apazone↗